Business Wire

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries

Jaa

Family-owned pharmaceutical company Boehringer Ingelheim today presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted). With a high percentage of first-in-class and breakthrough potential drug candidates, Boehringer Ingelheim continues the successful implementation of its R&D strategy.

Boehringer Ingelheim is committing more than €20 billion to Research & Development for human pharmaceuticals by 2025. In the past four years, the company received 14 regulatory approvals in several new indications, including four new molecular entities and four breakthrough designations by the US Food and Drug Administration.

“The most ambitious goal for researchers is to achieve a medical breakthrough for patients from our over 80 clinical and pre-clinical projects. Some 65% of our drug pipeline candidates already have breakthrough and/or first-in-class potential, and we aim for even more” said Dr Michel Pairet, Member of the Board of Managing Directors, responsible for Boehringer Ingelheim’s Innovation Unit, “Transcending disease boundaries is about looking at R&D with fresh eyes.”

To fulfil such aspirations, Boehringer Ingelheim embraces risks to dig deep into the mechanisms of diseases, to integrate the latest scientific and technological advances, and to work with the best partners to discover and deliver new medicines.

“Our worldwide team of 8,000 scientists, medical doctors and other contributors is truly motivated by our pipeline, its progress and what this could mean for patients.” commented Dr Christopher Corsico, Chief Medical Officer, Boehringer Ingelheim. “With ongoing work on a first-in-class inhibitor targeting inflammatory skin and bowel diseases, transformative oncology candidates, a promising schizophrenia prevention strategy and major indications for two of our blockbusters, Ofev® in lung fibrosis and Jardiance® in chronic kidney disease and chronic heart failure, we look forward to bringing years of health and improved quality of life to millions of people.”

To support and complement its own R&D, Boehringer Ingelheim is increasing the emphasis on external collaborations and expanding the community of innovation partners. The company currently works with over 70 innovative partners in universities, scientific institutions and biotech companies.

“Our long-lasting relationships with our partners are built on respect, empathy, trust and passion – values which foster an environment where synergies are realized, resulting in the potential for faster and better results.” said Dr Michel Pairet. “Our long-term, unwavering commitment to researching and developing new medicines will bring the transformative medicines that patients need.”

Highlights of Latest Boehringer Ingelheim Pipeline Progress

Immunology

In Immunology Boehringer Ingelheim’s IL-36 receptor inhibitor has the potential to transform the standard-of-care for patients with immune-mediated diseases.

BI 655130, a new biological entity and first-in-class IL-36 receptor antibody, has shown strong efficacy in early clinical testing with a single dose in patients affected by Generalized Pustular Psoriasis. These results support a broad potential in multiple inflammatory diseases.

Trials are underway in further immune-mediated diseases of the skin and intestine including Palmo-Plantar Pustulosis, Ulcerative Colitis, Crohn’s Disease, and other chronic inflammatory conditions.

Oncology

Boehringer Ingelheim is exploring therapies that target tumour cells directly in pathways so far ‘undrugged’. In Immune Oncology, the research teams are “turning up the heat on cancer” with therapies that activate the abilities of the patient’s own immune system and by bringing together smart and highly promising combinations of both types of therapies.

We are advancing combinations of immune-cell targeted therapies e.g. cancer vaccines, oncolytic viruses and T-cell engagers, as well as immunogenic cell death inducers such as our SMAC mimetic with BI 754091, a PD-1 checkpoint inhibitor.

In cancer cell directed projects, Boehringer Ingelheim’s oncology research portfolio includes more than 10 clinical-stage assets. We are working on new drug candidates in pathways such as KRAS, WNT and p53, and will move towards clinical trials for many of these in the next 12-24 months.

Central Nervous System

In CNS, Boehringer Ingelheim has expanded its PDE9 inhibition research programs to the prevention of relapse in schizophrenia and also in the prevention of first episode psychosis.

Boehringer Ingelheim’s research approach in CNS is taking a courageous “against the current” approach. The focus is on understanding how underlying malfunctions in brain circuitry manifest in specific symptoms and traits of mental illnesses. This is key to going beyond the current disease classifications which do not reflect the underlying disease mechanisms.

Boehringer Ingelheim investigates a range of mental disorders such as schizophrenia, Alzheimer’s disease and depression.

Fibrosis (Respiratory and Cardiometabolic Diseases)

Based on the pathophysiological and mechanistic parallels of fibrotic diseases, Boehringer Ingelheim is investigating its compound nintedanib in a wide spectrum of fibrosing Interstitial Lung Diseases (ILDs).

Two Phase III clinical trials are exploring the efficacy and safety of nintedanib (OFEV®) in Systemic Sclerosis ILD (SSc-ILD) and Progressive Fibrosing ILD (PF-ILD). The SENSCIS study has completed enrolment and may end in December 2018. The INBUILD study is likely to complete enrolment in Q2 2018.

In NASH, another fibrotic disease affecting the liver, Boehringer Ingelheim applies its deep understanding of the metabolic, inflammatory and fibrotic components of the disease and is investigating a frontrunner compound, an AOC3 inhibitor, in a Phase II clinical trial.

Cardiometabolic Diseases

In Cardiometabolic diseases, Boehringer Ingelheim is building on the strength of the results of the EMPA-REG OUTCOME® trial to explore the potential benefits of empagliflozin (JARDIANCE®1) beyond diabetes. Boehringer Ingelheim is investigating the potential of empagliflozin to protect patients with and without diabetes from the risk of chronic kidney disease and chronic heart failure.

Phase III studies are underway investigating the effects of empagliflozin in patients with Chronic Kidney Disease (CKD) and in patients with Chronic Heart Failure (CHF). The EMPA-KIDNEY and EMPEROR HEART FAILURE studies are expected to read out between 2019 and 2020.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com

1 Jardiance® is jointly marketed by Boehringer Ingelheim and Eli Lilly and Company.

Contact information

Boehringer Ingelheim Corporate Center GmbH
Dr. Reinhard Malin
Head of Communications, Innovation Unit
Media + PR
Phone: +49 6132 77-90815
press@boehringer-ingelheim.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Rockwell Automation Opens Registration for 2018 Automation Fair18.9.2018 17:54Tiedote

Registration is now open for the 2018 Automation Fair, hosted by Rockwell Automation and members of its global PartnerNetwork program. The 27th annual Automation Fair will be held Nov. 12-15 at the Pennsylvania Convention Center. The event brings together approximately 10,000 manufacturers and producers from across the globe to learn about the newest innovations in automation and take part in training, industry forums and networking events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005725/en/ Automation Fair will feature more than 150 exhibits showcasing the latest product innovations for industrial manufacturing and production. Hosted by Rockwell Automation and members of its PartnerNetwork, the event offers more than 400 hours of educational opportunities through forums, hands-on labs and technical sessions. (Photo: Business Wire) “The next industrial transformation is here – and meeting its demands requires a m

Seoul Semiconductor Supplies Optimal LEDs ‘SunLike’ to Large Scale Applications of Lumitronix in Germany18.9.2018 16:33Tiedote

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, supplied the innovative LEDs “SunLike” to Lumitronix, the LED specialist located in Baden-Württemberg, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005626/en/ The Modules with SunLike LEDs. (Photo: Business Wire) In cooperation with Seoul Semiconductor, Lumitronix has also developed three optimal SunLike modules to provide customers with a standardized solution and expand its adoption in the lighting market. Two of the LED modules comply with the standard of Zhaga, a global association of lighting companies, for Book 7 L56W2 and Book 7 L28W2 and enable easy replacement in various industrial applications. The modules named LinearZ are available in one feet and two feet length. The model LinearZ 280-26 measures 280 mm and is equipped with 26 SunLike LEDs and has a light output of up to 700 lm.

Andersen Global Continues South American Expansion With BKM Berkemeyer18.9.2018 16:30Tiedote

Andersen Global announces further growth in South America with the signing of a Collaboration Agreement with BKM Berkemeyer, one of the oldest and largest law firms in Paraguay. With two locations in the capital city of Asunción, the firm has a headcount of nearly 150 professionals, including ten Partners and over 60 lawyers. Established in 1951, BKM Berkemeyer is led by Managing Partner Hugo Berkemeyer and provides legal solutions to both domestic and international clients. The firm delivers advice in all areas of law, including business and corporate, taxation, litigation, environment, employment and intellectual property, with a notable expertise in international transactions and business matters. BKM Berkemeyer also specializes in M&A’s, joint ventures, foreign investment, infrastructure, project finance and financial transactions, advising also on issues regarding telecommunications, water and energy projects. Hugo commented, “Our focus at BKM Berkemeyer has been to provide flexib

175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis18.9.2018 16:05Tiedote

Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep apnoea, meaning they experience at least 15 breathing events an hour during sleep. These statistics are based on the latest scoring rules for determining one’s apnoea–hypopnoea index (AASM 2012) and are connected with a 16-country study announced in May 2018 that revealed an estimated 936 million people worldwide have sleep apnoea, a chronic sleep-disordered breathing condition associated with increased risk of mortality and reduced quality of life. The new global prevalence is nearly tenfold higher than the previous one – 100 million – estimated by the World Health Organization in 2007. European countries with the highest prevalence are: Russia, 40 million Germany, 26 million France, 24 million Ukraine, 13 million Sp

Veteran Gartner Analyst Pat Phelan Joins Rimini Street as VP of Market Research18.9.2018 16:00Tiedote

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of Pat Phelan as vice president of market research. In this new role, Phelan is responsible for research across the enterprise software market, including applications and technology strategies, software vendor support, third-party support, IT leadership trends and IT optimization. She also supports strategic planning, senior leadership discussions, business development and sales execution by providing enterprise software licensees with quantitative and qualitative strategic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005304/en/ Veteran Gartner Analyst Pat Phelan Joins Rimini Street as VP of Market Research (Photo: Business Wire) “As a Gartner analyst, I closely followed Rimini Street since its

AGCO Launches AGCO Agriculture Foundation18.9.2018 16:00Tiedote

AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announced the launch of the AGCO Agriculture Foundation. “The AGCO Agriculture Foundation is a testament to our commitment to support farmers feeding the world. Our objective is to support non-profit initiatives that contribute to global food security, support sustainable agriculture development and have an economic impact in developing countries,” said Martin Richenhagen, AGCO’s Chairman, President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005073/en/ The new philanthropic focus demonstrates AGCO’s strong commitment to specific Sustainable Development Goals developed by the United Nations that seek to end hunger and provide basic necessities to a growing world population. AGCO has already been driving change globally, particularly in certain developing markets, by supporting farmer

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme